Potassium Channels as the Next Major Opportunity in Pain Therapeutics

2:00 pm - Thursday 28th January 2027

  • Understanding how Kv7 potassium channel activation reduces neuronal hyperexcitability to suppress pain signalling at its source
  • Leveraging lessons from clinically validated Kv7 programs to accelerate development in pain indications
  • Understanding the scientific rationale for pairing selective NaV1.7 inhibition with Kv7.2/7.3 activation to more effectively reduce sensory neuron hyperexcitability
  • Assessing the long-term potential of Kv7 activators across neuropathic, inflammatory and musculoskeletal pain populations

Speakers:

Chief Medical Officer
Xenon Pharmaceuticals